The global market for neurological disease treatment and medication was worth $12.6 billion in 2006 and will reach $14 billion by 2007. At a compound annual growth rate (CAGR) of 11.6%, the global market will be worth almost $24.3 billion by 2012.
Drugs for multiple sclerosis, Alzheimer's disease, and Parkinson's disease control approximately 99% of the total market share.
Medications for multiple sclerosis are just over 35% greater than the market share of medication for Alzheimer's disease, despite the fact that there are far fewer patients with MS. As AD drugs become more prevalent, the shares of the market could change dramatically.
GLOBAL MARKET FORECAST FOR BRANDED MEDICATIONS FOR NEURODEGENERATIVE DISORDERS, 2006-2012
Source: BCC Research
This study examines trends in drug discovery and development for neurodegenerative disorders. Diseases examined include Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), the muscular dystrophies (MD), multiple sclerosis (MS), Parkinson's disease (PD), and Batten disease (BD) and Niemann-Pick disease (NPD), two rare disorders for which treatments exist or are in clinical trials.
It examines medications approved by regulatory agencies as well as candidate drugs in clinical trials. Sponsors range from large companies such as Wyeth to smaller ones, such as PTC Therapeutics and Amorfix. Trends in financing and business approaches are examined, as are strategies for commercializing new products. The report also makes predictions about technologies and approaches that are more or less likely to succeed, and how they are likely to grow in the next 5 years.
SCOPE OF STUDY
This report contains:
- An analysis of the trends in drug discovery and development for the neurodegenerative disorders
- An overview of the global neurological disorders treatment market which provides definitions and a structure for the industry
- Provides details for the treatment markets of specific diseases such as Alzheimer's, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, muscular dystrophy, and other, rarer neurological disorders
- Offers a detailed analysis of patents as well as important technological developments
- A review of government regulations
- Profiles the most important companies in the industry today.
METHODOLOGY AND INFORMATION SOURCES
The material for this report was gathered from interviews with individuals in the industry, as well as a thorough review of technology gathered from secondary sources. These sources include company annual, 10K, and 10Q reports, company literature, trade literature, trade associations, and online sources.
Projections were based on current and historical levels of funding and revenues, potential end users, likely unit prices, and rates of consumption. Final projections are based on the analysis of information from primary and secondary sources. All dollar projections are presented in year 2007 constant dollars and have been rounded.
ABOUT THE AUTHOR
Valerie Natale received a Ph.D. in cell biology from the University of Bern, Switzerland. She has held management-level positions in the biotechnology industry, and has written four other reports for BCC Research, in addition to other consulting work in the biotechnology industry. She is also involved in the development of a therapeutic agent for amyotrophic lateral sclerosis.